IDH2 and central nervous system cancer: We retrospectively examined the contrast enhanced T1-weighted MRI imaging of a large cohort (n = 587) of exclusively IDH mutant glioma patients, identified all instances of CEnew, and determined the incidence, characteristics, and survival implications of CEnew, PsP, and TP.